Brief: Tobira Therapeutics and DONG-A ST enter into license agreements for evogliptin and cenicriviroc

Dong-A ST

11/04/2016 12:58

April 11 (Reuters) - Tobira Therapeutics Inc  TBRA.O  
    * Co and DONG-A ST enter into license agreements for 
evogliptin and cenicriviroc 
    * Tobira has acquired exclusive rights to develop and market 
evogliptin in combination with cenicriviroc 
    * Acquired exclusive rights to develop, market evogliptin in 
United States, Canada, Europe, Australia for all therapeutic 
indications 
    * Under terms of agreement, DONG-A received an upfront cash 
payment of $1.5 million 
    * Dong-A eligible to receive up to an additional $25 million 
in payments 
    * Dong-A may receive up to an additional $35 million for 
commercial milestones 
    * Received an upfront cash payment of $0.5 million and is 
eligible to receive up to an additional $2.5 million in payments 
    * In addition, each party will receive tiered royalty 
payments based on net sales. 
 
Source text for Eikon:  ID:nPn76fLzra  
Further company coverage:  TBRA.O  
 
 (Bengaluru Newsroom: +1 646 223 8780)